The global contrast-enhanced ultrasound market is projected to reach USD 2.1 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 6.1% from 2023 to 2028. The rising number of targeted diseases and advancements in ultrasound technology fuel the market growth. The contrast-enhanced ultrasound market is moderately competitive, with established companies and upcoming competitors for the same market share. As of 2022, the key players operating in the global contrast-enhanced ultrasound market are GE Healthcare (US), Lantheus Holdings, Inc. (US), Bracco Imaging SpA (Italy), Koninklijke Philips N.V. (Netherlands), among others.
These competitors have utilized various strategies to increase their market share in the global contrast-enhanced ultrasound market, including acquisitions, agreements, partnerships, and product releases. In 2022, a higher share of the contrast-enhanced ultrasound market was held by GE Healthcare (US), Lantheus Holdings, Inc. (US), and Bracco Imaging SpA (Italy).
To know about the assumptions considered for the study download the pdf brochure
GE Healthcare (US):
GE Healthcare is headquartered in Illinois, US. The company offers a comprehensive product portfolio in medical diagnostics, medical imaging & information technologies, disease research, drug discovery, and biopharmaceutical manufacturing technologies. Its medical diagnostics and medical imaging portfolio includes various diagnostic solutions such as molecular imaging, ultrasound, and magnetic resonance imaging technologies.
GE HealthCare has a wide geographic presence in more than 140 countries across North America, South America, Europe, the Middle East, the Asia Pacific, and Africa. The company has adopted inorganic growth strategies such as acquisitions to strengthen its market position.
Lantheus Holdings, Inc. (US):
Latheus is involved in providing a range of diagnostic and therapeutic solutions. It is one of the leading players in the diagnostic imaging segment. The company offers contrast agents for PET and ultrasound, a technetium-based generator used in nuclear medicine procedures, PYLARIFY AI platform that assists with evaluating PET images, among others. The company has offices located in New Jersey, Massachusetts, Canada, and Sweden. The company offers Definity (Luminity) contrast agents for ultrasound procedures.
Lantheus Holdings, inc. is the parent organization of Lantheus Medical Imaging, Inc., EXINI Diagnostics AB, and Progenics Pharmaceuticals, Inc. The company offers diagnostic imaging-related solutions through the subsidiary Lantheus Medical Imaging, Inc. The company is headquartered in the US and provides its solutions globally through a number of distributors.
Bracco Imaging SpA (Italy)
Bracco Imaging is a global leader in diagnostic imaging and is a part of the Bracco group. The company develops, manufactures, and commercializes diagnostic imaging agents and solutions, including medical devices, software, and administration systems. It provides novel solutions for different imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, and contrast-enhanced ultrasound (CEUS), among others. It provides an ultrasound-enhanced agent called Lumason (SonoVue) and software for CEUS.
The company has its manufacturing sites located in different areas in North America, Europe, Japan, China, Mexico, Brazil, and South Korea. The company has a remarkable presence in more than 100 countries worldwide, either directly or indirectly, via different distributors.
Contrast Enhanced Ultrasound Market by Product (Equipment, Nanoparticle & Molecule-targeted Microbubbles, Software], Application (Diagnostic, Therapeutic, CVDs, Liver, Kidney, Oncology), End-User (Hospital, Clinics, ASCs) & Region Global Forecasts to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE